drugset / Trial / NCT06408246

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

NCT06408246

Phase 2 Recruiting 162 enrolled Stanford University
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

Timeline

Start
2026-03-03
Primary completion
2028-10-01
Completion
2029-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule
Background Sertraline Small molecule

Indications